Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

ate Phase 2 trials of BSI-201, reflecting the breadth of tumor types that could be sensitive to the drug."

The company is currently conducting a Phase 2 trial of BSI-201 in triple- negative breast cancer and is collaborating with the New Approaches to Brain Tumor Therapy (NABTT) consortium, a National Cancer Institute-funded research group, to test BSI-201 in glioblastoma multiforme (GBM), the most common brain cancer in adults. An additional trial in uterine cancer is expected to begin enrollment in the coming weeks. The company also plans to present data from its Phase 1 trials of BSI-201 in solid tumors at the American Society of Clinical Oncology Annual Meeting that begins later this month in Chicago.

About BiPar Sciences

BiPar Sciences is a drug development company with a therapeutic focus on exploring novel mechanisms of action in oncology. The lead development program is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. The lead product within that program is BSI-201, a platform drug with the potential to be a superior new treatment across a range of tumor types, both as monotherapy and in combination with chemotherapy. The company is currently testing BSI-201 in a range of Phase 2 trials in breast, brain and ovarian cancer.


'/>"/>
SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...- Alpharma Inc. (NYSE: ALO ),a global specialty ...om,clinical trials that showed ALO-01 (EMBEDA(TM))...ed naltrexone hydrochloride) capsules,demonstrated...bility,alongside a promising safety and efficacy p...he 27th Annual Scientific Session of the American,...
(Date:5/8/2008)...herapeutic Proteins at Tumor,Site, ARLINGTON HE...g gene,therapy, plastic surgeons have delivered ca...n cancerous tumors on rats with a 79 percent reduc...May issue of Plastic and,Reconstructive Surgery(R)...iety of Plastic Surgeons (ASPS). This new delivery...
(Date:5/8/2008)...f the American Pain Society ...-- Patients treated with lacosamide,demonstrated s...n (DNP),compared to placebo-treated patients, acc...g of the American Pain Society (APS) in Tampa, Fla... a diabetic neuropathic,pain treatment providing e...
(Date:5/8/2008)...stigators to Assess BSI-201 Therapy in B... Calif., May 8 /- BiPar Sciences, Inc...l trial programs for its lead,product, BSI-201, in...trial,of BSI-201 that BiPar has launched in the pa...t and brain cancer., The company is evaluating BS...
Breaking Medicine Technology:Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on Tapestry Pharmaceuticals Inc 973 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on Tapestry Pharmaceuticals Inc 973 2Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on Tapestry Pharmaceuticals Inc 973 3CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation 969 1CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation 969 2Novel Angiogenic Drugs Including a Future Blockbuster from Genzyme Could Revolutionize Treatment of Peripheral Arterial Disease 492 1Novel Angiogenic Drugs Including a Future Blockbuster from Genzyme Could Revolutionize Treatment of Peripheral Arterial Disease 492 2Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine 242 1Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine 242 2
...SINESS WIRE)--Apr 26, 2007 - A new study published...ology indicates,that a treatment from Medtronic, I...rebral palsy improves their quality of life and is...-effective,treatments. The findings of this Medtro...eatment, known as Medtronic ITB Therapy(SM),(Intra...
...idence for the Effectiveness of Hypertension,Treat... in Japanese,Patients, TOKYO, April 26, 2007 /Xinh...EI HEART Study, the large-scale clinical trial,hea...s today,published in the internationally renowned ...ore than 3,000 patients, is one of,the largest car...
Other Medicine Technology:Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 2Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 3Study Supports Cost-Effectiveness of Medtronic's Spasticity,Treatment for Children with Cerebral Palsy 4First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 2First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 3First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan 4
(Date:5/9/2008)... TUSTIN, Calif., May 9 /PRNewswire-FirstCall/ --...ally integrated specialty pharmaceutical company,w...ubsidiary, Jade,Pharmaceutical Inc., today announc...the year ended December 31, 2007, which were inclu...he Securities and Exchange,Commission on April 14,...
(Date:5/9/2008)... First Medication Indicated for Maintenance T...e-FirstCall/ -- Eli Lilly and Company,(NYSE: LLY ...Drug,Administration (FDA) has approved Strattera(R...ttention-Deficit/Hyperactivity Disorder (ADHD) in,...orepinephrine reuptake,inhibitor, is the first FDA...
(Date:5/9/2008)... SAN DIEGO, May 9 /PRNewswire/ -- Summary: With ...an estimated 100,000 deaths and leaving over a,mil...mmense. Internet,entrepreneurs Sharon Tucci and St...rassroots effort to award awareness for humanitari...s possible. Setting an initial goal,of having 1,00...
(Date:5/9/2008)... EVANSTON, Ill., May 9 /PRNewswire-USNewswire/ -... effort to help relieve the unspeakable human,suff...ecial donation kiosks,have been developed and are ...ual world of Second Life, with coordination being ... main island,( http://slurl.com/secondlife/Simuali...
Breaking Medicine News(10 mins):Health News:AMDL Reports Going Concern Qualification 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6Health News:New Web Site to Raise Awareness for the Myanmar Crisis Has Lofty Goals 2
...nning on launching a program to improve the care, ...dren in Zimbabwe//, where one child dies of AIDS a...ement Wednesday, UNICEF Britain has acknowledged t...tening Zimbabwe's children and has given UNICEF ?2...
...of the world's largest and leading confectionery m...n business, Monkhill//. It is basically a London ... dispose off its non-core assets. The sale of Mo...our manufacturing plants and one distribution depo...
...eservation of postgraduate medical seats to in-ser...Tuesday the Government announced that these candid...mum specified period upon completion of the PG deg...y a default fine of Rs 20 lakhs. The government’s...
...rsed the new Medicare prescription drug benefit an... up before the May 15 deadline. // "It doesn't cos... said Bush. "Seniors are saving about half on thei...you're a poor senior, the government is going to p...
Other Medicine News:Health News:UNICEF To Launch A Programme For Zimbabwe Children 2
Compact networked patient monitors for flexible care.
... monitoring, IntelliVue has highly flexible screen... menu; built-in clinical support tools such as Eve...rhythmia analysis; and many other powerful feature...networked platform that can span the hospital ente...
...power of the Nightingale system is further magnifi...s to Zoe Medical's Online Care Unit™ (OCU). ... that serves as a secure, central clearinghouse fo...e Monitoring System that has been configured to ha...
Generra Narkotron II is a comprehensive vital sign monitor. , ,Adult, pediatric, and neonatal. , ,Providing high quality, affordable products for efficiency in patient care., ,Standard Functions:
Medicine Products: